BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 15, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Androxal enclomiphene regulatory update

Repros submitted a revised indication statement and a literature review to FDA's Division of Reproductive and Urologic Products in response to questions raised by FDA in a Jan. 25 meeting for Androxal enclomiphene to treat...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >